A retrospective database analysis to assess the clinical utility of liquid biopsy-based cancer genome profiling in real-world practice

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1030250325

Enrollment

5000

Registered

2025-08-29

Start date

2025-08-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumor

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: All cases registered in the C-CAT database between July 1, 2023, and the end date of the study period

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1. Cases lacking essential genomic or clinical data for analysis 2. Cases of rare cancers or diseases with a sample size of 10 or fewer

Design outcomes

Primary

Measure	Time frame
1. Detection rate of clinically actionable genomic alterations via CGP testing, ctDNA detection rate, ctDNA quantity, turnaround time from sample collection or registration to expert panel meeting or start of systemic therapy 2. Rate of therapeutic agents recommended based on CGP results, rate of administration of recommended therapies, treatment response, progression-free survival (PFS), overall survival (OS)	—

Measure

Time frame

1. Detection rate of clinically actionable genomic alterations via CGP testing, ctDNA detection rate, ctDNA quantity, turnaround time from sample collection or registration to expert panel meeting or start of systemic therapy 2. Rate of therapeutic agents recommended based on CGP results, rate of administration of recommended therapies, treatment response, progression-free survival (PFS), overall survival (OS)

—

Contacts

Public ContactTaku Murakami

Guardant Health Japan Corp.

tmurakami@guardanthealth.com+81-3-4545-1341

Outcome results